Unraveling Alzheimer’s: Making Sense of the Relationship between Diabetes and Alzheimer’s Disease
暂无分享,去创建一个
[1] C. Hölscher,et al. Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence , 2013, CNS Drugs.
[2] R. Stewart,et al. Type 2 diabetes mellitus, cognitive impairment and dementia , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[3] T. Montine,et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. , 2005, Archives of neurology.
[4] L. V. Van Eldik,et al. Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin , 2014, Molecular Neurodegeneration.
[5] H. Lipp,et al. Lack of neprilysin suffices to generate murine amyloid‐like deposits in the brain and behavioral deficit in vivo , 2006, Journal of neuroscience research.
[6] Tao Wang,et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model , 2010, Molecular Neurodegeneration.
[7] F. Hamel,et al. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. , 2009, Biochemical pharmacology.
[8] A. Dedeoglu,et al. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease , 2014, Molecular Psychiatry.
[9] L. Hersh,et al. Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] L. Hersh,et al. Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.
[11] R. Mayeux,et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. , 2001, American journal of epidemiology.
[12] Prasanthi,et al. Molecular Neurodegeneration Differential Effects of 24-hydroxycholesterol and 27-hydroxycholesterol on Β-amyloid Precursor Protein Levels and Processing in Human Neuroblastoma Sh-sy5y Cells , 2022 .
[13] M. Leissring,et al. Deletion of Insulin-Degrading Enzyme Elicits Antipodal, Age-Dependent Effects on Glucose and Insulin Tolerance , 2011, PloS one.
[14] S. Leurgans,et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.
[15] J. Mcdermott,et al. Degradation of Alzheimer's ß-Amyloid Protein by Human and Rat Brain Peptidases: Involvement of Insulin-Degrading Enzyme , 2004, Neurochemical Research.
[16] W. Duckworth. Insulin degradation: mechanisms, products, and significance. , 1988, Endocrine reviews.
[17] G. Wilcock,et al. Hyperinsulinaemia and Alzheimer's disease. , 1994, Age and ageing.
[18] M. Leissring,et al. Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.
[19] A. Boschero,et al. Reduced insulin clearance and lower insulin-degrading enzyme expression in the liver might contribute to the thrifty phenotype of protein-restricted mice , 2014, British Journal of Nutrition.
[20] P. O'Brien,et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.
[21] D. Selkoe,et al. Degradation of Amyloid -Protein by a Serine Protease--Macroglobulin Complex (*) , 1996, The Journal of Biological Chemistry.
[22] R. Au,et al. Positive association between plasma amylin and cognition in a homebound elderly population. , 2014, Journal of Alzheimer's disease : JAD.
[23] A. Korczyn. Why Have We Failed to Cure Alzheimer's Disease? , 2014, Neurobiology of Aging.
[24] D. Bennett,et al. LONG-TERM FETAL CELL TRANSPLANT IN HUNTINGTON DISEASE: STAYIN’ ALIVE , 2007, Neurology.
[25] S. Resnick,et al. Midlife adiposity predicts earlier onset of Alzheimer’s dementia, neuropathology and presymptomatic cerebral amyloid accumulation , 2015, Molecular Psychiatry.
[26] Y. Itzhak,et al. Long-term parental methamphetamine exposure of mice influences behavior and hippocampal DNA methylation of the offspring , 2014, Molecular Psychiatry.
[27] W. Qiu,et al. Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease? , 2014, Front. Aging Neurosci..
[28] S. Craft,et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.
[29] Qian-kun Quan,et al. Ginsenoside Rg1 Decreases Aβ1–42 Level by Upregulating PPARγ and IDE Expression in the Hippocampus of a Rat Model of Alzheimer's Disease , 2013, PloS one.
[30] W. Duckworth,et al. Degradation of Amylin by Insulin-degrading Enzyme* , 2000, The Journal of Biological Chemistry.
[31] B. Winblad,et al. P4-040 Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study , 2004, Neurobiology of Aging.
[32] P. van Endert,et al. Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice , 2015, Nature Communications.
[33] L. Schneider,et al. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials , 2007, The Lancet Neurology.
[34] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[35] A Hofman,et al. Diabetes mellitus and the risk of dementia , 1999, Neurology.
[36] D. Bennett,et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.
[37] D. Selkoe,et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] A. Zmijewska,et al. Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.
[39] Nathan Herrmann,et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[40] D. Bennett,et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons , 2006, Neurology.
[41] P. Mehta,et al. Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.
[42] Eileen Crimmins,et al. The Value of Delaying Alzheimer’s Disease Onset , 2014, Forum for health economics & policy.
[43] R. Dankner,et al. Insulin Resistance and Hyperinsulinemia , 2008, Diabetes Care.
[44] P. Wittung-Stafshede,et al. Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner , 2015, Scientific Reports.
[45] B. Winblad,et al. Diabetes mellitus and risk of dementia in the Kungsholmen project , 2004, Neurology.
[46] M. MacCoss,et al. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism , 2006 .
[47] S. Rai,et al. Glial activation and post-synaptic neurotoxicity: The key events in Streptozotocin (ICV) induced memory impairment in rats , 2014, Pharmacology Biochemistry and Behavior.
[48] G. Schellenberg,et al. Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-ε4 Allele , 2003 .
[49] G. Zuliani,et al. Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. , 1999, Dementia and geriatric cognitive disorders.
[50] G. Schellenberg,et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.
[51] Paco Martorell,et al. Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.
[52] M. Ingelsson,et al. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. , 2015, The American journal of pathology.
[53] L. Launer,et al. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.
[54] D. Alkon,et al. Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.
[55] D. Selkoe,et al. Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme , 2000, The Journal of Neuroscience.
[56] J. Wands,et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.
[57] H. Hamazaki. Cathepsin D is involved in the clearance of Alzheimer's β‐amyloid protein , 1996 .
[58] Lixia Guo,et al. Geniposide regulates insulin-degrading enzyme expression to inhibit the cytotoxicity of Aβ₁₋₄₂ in cortical neurons. , 2012, CNS & neurological disorders drug targets.
[59] R. Mayeux,et al. Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.
[60] S. M. de la Monte. Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012, Current Alzheimer research.
[61] A. Hofman,et al. 312 Incidence of Alzheimer's disease and vascular dementia in the Rotterdam study , 1996, Neurobiology of Aging.
[62] C. Eckman,et al. Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention , 2005 .
[63] C. Eckman,et al. Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.
[64] T. Montine,et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .
[65] S. Love,et al. A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.
[66] D. Selkoe,et al. Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.
[67] D. Selkoe,et al. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. , 1996, Journal of Biological Chemistry.
[68] M. Leissring,et al. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway , 2009, Molecular Neurodegeneration.
[69] M. Leissring,et al. Regulation of distinct pools of amyloid β-protein by multiple cellular proteases , 2013, Alzheimer's Research & Therapy.
[70] I. Kurochkin,et al. Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme , 1994, FEBS letters.
[71] B. Teter,et al. Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention , 2004, The Journal of Neuroscience.
[72] J. Baird,et al. Diabetes mellitus and obesity , 1973, Proceedings of the Nutrition Society.
[73] C. Soto,et al. Cross-Seeding of Misfolded Proteins: Implications for Etiology and Pathogenesis of Protein Misfolding Diseases , 2013, PLoS pathogens.
[74] K. Akiyama,et al. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type , 1991, Biological Psychiatry.
[75] Chunyu Wang,et al. γ-Secretase Substrate Concentration Modulates the Aβ42/Aβ40 Ratio , 2007, Journal of Biological Chemistry.
[76] D. Ishii,et al. Systemic insulin‐like growth factor‐I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats , 2003, Journal of neuroscience research.
[77] S. Plesneva,et al. Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues , 2015, Biogerontology.
[78] N. Calcutt,et al. The Roles of Streptozotocin Neurotoxicity and Neutral Endopeptidase in Murine Experimental Diabetic Neuropathy , 2010, Experimental diabetes research.
[79] A. Mizisin,et al. Diabetes induces changes in ILK, PINCH and components of related pathways in the spinal cord of rats , 2010, Brain Research.
[80] A. Pfeiffer,et al. Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells , 2009, Diabetologia.
[81] L. Morelli,et al. The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme , 2008, Prion.
[82] Sarah A. Stern,et al. The effect of insulin and insulin-like growth factors on hippocampus- and amygdala-dependent long-term memory formation , 2014, Learning & memory.
[83] M. Reger,et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.
[84] M. Ohno,et al. Mechanisms Underlying Insulin Deficiency-Induced Acceleration of β-Amyloidosis in a Mouse Model of Alzheimer's Disease , 2012, PloS one.
[85] C. Bogardus,et al. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. , 2000, Diabetes.
[86] C. Östenson,et al. The Type 2 Diabetes–Associated Gene Ide Is Required for Insulin Secretion and Suppression of α-Synuclein Levels in β-Cells , 2013, Diabetes.
[87] V. Vingtdeux,et al. CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain , 2015, Journal of Cell Science.
[88] W. Pories. Hyperinsulinism as the culprit: surgery provides the evidence , 2012 .
[89] J. Cresto,et al. Degradation of Soluble Amyloid β-Peptides 1–40, 1–42, and the Dutch Variant 1–40Q by Insulin Degrading Enzyme from Alzheimer Disease and Control Brains , 2000, Neurochemical Research.
[90] Kristine Yaffe,et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.
[91] D. Selkoe,et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. , 2004, The American journal of pathology.
[92] J. Luchsinger. The Relationship Between the Continuum of Elevated Adiposity, Hyperinsulinemia, and Type 2 Diabetes and Late-onset Alzheimer’s Disease: An Epidemiological Perspective , 2010 .
[93] John Wilding,et al. Obesity and Diabetes , 2010, Experimental and Clinical Endocrinology & Diabetes.
[94] Matthew P. Frosch,et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[95] Mark T. W. Ebbert,et al. Genetics of Alzheimer's Disease , 2013, BioMed research international.
[96] U. Meyer,et al. Amylin at the interface between metabolic and neurodegenerative disorders , 2015, Front. Neurosci..
[97] G. Schellenberg,et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.
[98] D. Selkoe,et al. Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin , 2010, PloS one.
[99] J. Mcdermott,et al. Degradation of Alzheimer's beta-amyloid protein by human cathepsin D. , 1996, Neuroreport.
[100] Sarah A. Stern,et al. A critical role for IGF-II in memory consolidation and enhancement , 2011, Nature.
[101] K. Rockwood,et al. Diabetes mellitus and the Risk of Dementia, Alzheimer’s Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging , 2002, Dementia and Geriatric Cognitive Disorders.
[102] S. McGuire,et al. Centers for Disease Control and Prevention. State indicator report on Physical Activity, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014. , 2014, Advances in nutrition.
[103] Hyoung-Gon Lee,et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition , 2014, Neurobiology of Aging.
[104] J. Wands,et al. Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.
[105] J. Trojanowski,et al. Interactions of amyloidogenic proteins , 2007, NeuroMolecular Medicine.
[106] E. Masliah,et al. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice , 2010, Experimental Neurology.
[107] I. Kurochkin. Amyloidogenic determinant as a substrate recognition motif of insulin‐degrading enzyme , 1998, FEBS letters.
[108] C. Soto,et al. Are Amyloids Infectious , 2009 .
[109] S. Monte. Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease , 2012, Drugs.
[110] C. Soto,et al. Cross currents in protein misfolding disorders: interactions and therapy. , 2009, CNS & neurological disorders drug targets.
[111] R. Green,et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. , 2006, Archives of neurology.
[112] C. DeCarli,et al. Amylin deposition in the brain: A second amyloid in Alzheimer disease? , 2013, Annals of Neurology.
[113] M. Folstein,et al. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.
[114] J. Schneider,et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.